Divis Laboratories Ltd Stock Price Today (NSE: DIVISLAB)
Fundamental Score
Divis Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Divis Laboratories Ltd share price today is ₹6187.50, up +0.00% on NSE/BSE as of 17 February 2026. Divis Laboratories Ltd (DIVISLAB) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.70L (Cr). The 52-week high for DIVISLAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 68.59x, DIVISLAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.35% and a debt-to-equity ratio of 0.01.
Divis Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Divis Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Divis Laboratories Share Price: A ROCE Efficiency Analysis
In the dynamic pharmaceutical industry, characterized by stringent regulatory hurdles and lengthy R&D cycles, companies that efficiently allocate capital and generate returns stand out. This analysis focuses on Divis Laboratories share price and examines its Return on Capital Employed (ROCE) in relation to its valuation and peer performance. The current share price of ₹6024.5 reflects market expectations, which are further illuminated by its PE ratio of 68.59.
Divis Laboratories boasts a ROCE of 20.44%. This metric reveals how effectively the company utilizes its capital to generate profits. A higher ROCE generally indicates superior capital allocation. In Divis's case, a 20.44% ROCE suggests a competitive advantage and contributes to building a strong economic moat. Consistent high ROCE performance can create a virtuous cycle, allowing the company to reinvest profits strategically, further strengthening its market position and hindering competitors.
While a high ROCE is generally positive, it’s crucial to consider the context. The PE ratio of 68.59 suggests the market has high expectations for future growth. Comparing Divis Laboratories Ltd with sector peers provides valuable context. For example, examining companies like
Mankind Pharma Ltd and their management’s capital allocation strategies can offer insights into whether Divis is optimally deploying its resources. A thorough investigation of competitors like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd will offer a broader sense of the range of ROCE within the sector.Ultimately, a sustained high ROCE strengthens a company's resilience and ability to weather industry challenges. The interplay between Divis Laboratories' ROCE, valuation, and its strategic positioning indicates the long-term potential of the firm. This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra, designed to provide a comprehensive overview of the company's financial health and operational efficiency. Please note this is an observational analysis and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Divis Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DIVISLAB across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (15.35%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.44%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (34.98%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (35.10%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.12%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (270.58x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹4695.21 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.89%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 39.07%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 68.59x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Divis Laboratories Ltd Financial Statements
Comprehensive financial data for Divis Laboratories Ltd including income statement, balance sheet and cash flow
About DIVISLAB (Divis Laboratories Ltd)
Divis Laboratories Ltd (DIVISLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.70L (Cr). Divis Laboratories Ltd has delivered a Return on Equity (ROE) of 15.35% and a ROCE of 20.44%. The debt-to-equity ratio stands at 0.01, reflecting the company's capital structure. Investors tracking DIVISLAB share price can monitor key metrics including P/E ratio, promoter holding of 51.89%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
DIVISLAB Share Price: Frequently Asked Questions
What is the current share price of Divis Laboratories Ltd (DIVISLAB)?
As of 17 Feb 2026, 10:09 am IST, Divis Laboratories Ltd share price is ₹6187.50. The DIVISLAB stock has a market capitalisation of ₹1.70L (Cr) on NSE/BSE.
Is DIVISLAB share price Overvalued or Undervalued?
DIVISLAB share price is currently trading at a P/E ratio of 68.59x, compared to the industry average of 31.77x. Based on this relative valuation, the Divis Laboratories Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of DIVISLAB share price?
The 52-week high of DIVISLAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Divis Laboratories Ltd share price?
Key factors influencing DIVISLAB share price include quarterly earnings growth (Sales Growth: 16.12%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Divis Laboratories Ltd a good stock for long-term investment?
Divis Laboratories Ltd shows a 5-year Profit Growth of 10.41% and an ROE of 15.35%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in DIVISLAB shares.
How does Divis Laboratories Ltd compare with its industry peers?
Divis Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare DIVISLAB share price P/E of 68.59x and ROE of 15.35% against the industry averages to determine competitive standing.
What is the P/E ratio of DIVISLAB and what does it mean?
DIVISLAB share price has a P/E ratio of 68.59x compared to the industry average of 31.77x. Investors pay ₹69 for every ₹1 of annual earnings.
How is DIVISLAB performing according to Bull Run's analysis?
DIVISLAB has a Bull Run fundamental score of 67.9/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does DIVISLAB belong to?
DIVISLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Divis Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for DIVISLAB?
DIVISLAB has an ROE of 15.35%, which indicates excellent management efficiency. ROE measures how efficiently Divis Laboratories Ltd generates profits from shareholders capital.
How is DIVISLAB debt-to-equity ratio and what does it indicate?
DIVISLAB has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.
What is DIVISLAB dividend yield and is it a good dividend stock?
DIVISLAB offers a dividend yield of 0.47%, meaning you receive ₹0.47 annual dividend for every ₹100 invested in Divis Laboratories Ltd shares.
How has DIVISLAB share price grown over the past 5 years?
DIVISLAB has achieved 5-year growth rates of: Sales Growth 11.65%, Profit Growth 10.41%, and EPS Growth 10.41%.
What is the promoter holding in DIVISLAB and why does it matter?
Promoters hold 51.89% of DIVISLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Divis Laboratories Ltd.
What is DIVISLAB market capitalisation category?
DIVISLAB has a market capitalisation of ₹170446 crores, placing it in the Large-cap category.
How volatile is DIVISLAB stock?
DIVISLAB has a beta of N/A. A beta > 1 suggests the Divis Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is DIVISLAB operating profit margin trend?
DIVISLAB has a 5-year average Operating Profit Margin (OPM) of 34.98%, indicating the company's operational efficiency.
How is DIVISLAB quarterly performance?
Recent quarterly performance shows Divis Laboratories Ltd YoY Sales Growth of 16.12% and YoY Profit Growth of 35.10%.
What is the institutional holding pattern in DIVISLAB?
DIVISLAB has FII holding of 19.39% and DII holding of 19.68%. Significant institutional holding often suggests professional confidence in the Divis Laboratories Ltd stock.